| Ytd | 6.94% | |
| 1y | -1.82% |
| Open | 7.12 | Prev Close | 7.18 | Low | 7.10 | High | 7.56 | Mkt Cap | 800.55M |
| Vol | 1.20M | Avg Vol | 81.83K | EPS | -0.21 | P/E | N/A | Forward P/E | 25.22 |
| Beta | 1.92 | Short Ratio | 21.22 | Inst. Own | 1.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 6.49 | 200-d Avg | 7.11 | 1yr Est | 0.00 |
GYRE News
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or th
Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.12 per share versus the Zacks Co
Gyre Therapeutics (NASDAQ:GYRE) affirms FY2026 sales outlook from $100.500 million-$111.000 million
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.12) per share which missed the anal
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or
Newtown Square, Pennsylvania--(Newsfile Corp. - May 27, 2026) - Kaskela Law LLC is investigating Gyr
GYRE, FSUN and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2026.
Gyre Therapeutics, Inc. ("Gyre", "Gyre Therapeutics" or the "Company") (NASD
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or
Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.05 per share versus the Zacks Co
Gyre Therapeutics (NASDAQ:GYRE) affirms FY2026 sales outlook from $100.500 million-$111.000 million
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.04) per share which beat the analys
Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5
Post-closing combined company has revenue-producing commercial asset and a robust pipeline of produc
Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (NASDAQ:GYRE), a San Diego-based innovative comm
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (N
Gyre Therapeutics, Inc. (GYRE) came out with quarterly earnings of $0.04 per share, missing the Zack
Gyre Therapeutics (NASDAQ:GYRE) sees FY2026 sales of $100.500 million-$111.000 million vs $146.133 m
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.05 per share which missed the anal
Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range
Tenax Therapeutics (NASDAQ: TENX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free R
Gyre Therapeutics, Inc. (Gyre or the Company) (NASDAQ:GYRE), an innovative, commercial-stage biophar
Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with reve
ImmunityBio (NASDAQ: IBRX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free Report)
Gyre Pharmaceuticals completed a Pre-NDA meeting with China's CDE, which agreed that the existin
Gyre Pharmaceuticals completed a Pre-NDA meeting with China's CDE, which agreed that the existing Ph
Gyre Therapeutics, Inc. (GYRE) came out with quarterly earnings of $0.06 per share, beating the Zack
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.03 per share which beat the analys
Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025,
GYRE, DAR and CRLBF have been added to the Zacks Rank #5 (Strong Sell) List on October 17, 2025.
HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billi
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-th
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enl